6533b85bfe1ef96bd12ba164
RESEARCH PRODUCT
Adding chemotherapy to TKI: Can we improve first-line treatment for EGFR-mutated NSCLC patients?
Antonio RussoFrancesco Passigliasubject
Oncologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingCancer Researchmedicine.medical_treatmentPopulationOncology; Radiology Nuclear Medicine and Imaging; Cancer Researchlaw.inventionOncology; Radiology; Nuclear Medicine and Imaging; Cancer ResearchGefitinibRandomized controlled triallawInternal medicineNuclear Medicine and ImagingmedicineProgression-free survivalEpidermal growth factor receptoreducationChemotherapyeducation.field_of_studybiologybusiness.industryHazard ratioSurgeryPemetrexedOncologybiology.proteinbusinessRadiologymedicine.drugdescription
In The Journal of Clinical Oncology , Ying Cheng and colleagues (1) have recently reported the results of a phase II randomized trial comparing pemetrexed plus gefitinib vs. gefitinib in treatment-naive, East Asian patients, with advanced non-squamous non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. The study met its primary end-point in the intent-to-treat population, showing a significantly longer median progression free survival (PFS) in favors of the combination arm (15.8 months) compared to single agent arm (10.9 months) [hazard ratio (HR): 0.68; 95% CI, 0.48 to 0.96; one-sided P=0.014; two-sided P=0.029].
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-12-01 |